An observational study to evaluate RAS gene status in blood in advanced colorectal cancer patients with RAS Mutatio
Not Applicable
Recruiting
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000043442
- Lead Sponsor
- Japan Clinical Cancer Research Organization (JACCRO)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Another malignancy with less than 5 disease-free years (2) Patients whose participation in the trial was judged to be inappropriate by the attending doctor
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the frequency of RAS wild in ctDNA
- Secondary Outcome Measures
Name Time Method (1) mutation allele frequency of RAS mutation in ctDNA (2) regarding all chemotherapies in enrolled patients overall response rate:ORR disease control rate:DCR overall survival:OS progression-free survival:PFS (3) regarding anti-EGFR antibody containing regimen in enrolled patients treatment cycle safety
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does ctDNA RAS mutation monitoring in JPRN-UMIN000043442 inform treatment resistance mechanisms in metastatic CRC?
What role do RAS mutations in circulating tumor DNA play in predicting response to anti-EGFR therapies in RAS-mutant CRC patients?
How does JACCRO CC-17 compare ctDNA RAS status to tissue biopsy for metastatic colorectal cancer patient stratification?
Which molecular biomarkers correlate with ctDNA RAS mutation clearance after chemotherapy in JPRN-UMIN000043442?
What targeted therapies are under investigation for RAS-mutant CRC based on ctDNA dynamics observed in JACCRO studies?